Adagene Inc
ADAG2.630USD
+0.090+3.54%
終値 02/06, 16:00（ET）15分遅れの株価
154.94M時価総額
損失額直近12ヶ月PER
詳細情報 Adagene Inc 企業名
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. The Company is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.
Adagene Incの企業情報
企業コードADAG
会社名Adagene Inc
上場日Feb 09, 2021
最高経営責任者「CEO」Luo (Peter)
従業員数138
証券種類Depository Receipt
決算期末Feb 09
本社所在地4F, Building C14, No. 218, Xinghu Street
都市SUZHOU
証券取引所NASDAQ OMX - NASDAQ BASIC
国China
郵便番号- -
電話番号8651287773632
ウェブサイトhttps://www.adagene.com/
企業コードADAG
上場日Feb 09, 2021
最高経営責任者「CEO」Luo (Peter)
Adagene Incの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Peter (Peizhi) Luo, Ph.D.
Dr. Peter (Peizhi) Luo, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
1.31M
-46664.00%
Dr. Fangyong (Felix) Du, Ph.D.
Dr. Fangyong (Felix) Du, Ph.D.
Chief Technology Officer
Chief Technology Officer
--
--
Dr. Xu Jc, M.D., Ph.D.
Dr. Xu Jc, M.D., Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Zhao Qinghai, Ph.D.
Mr. Zhao Qinghai, Ph.D.
Chief Manufacturing Officer
Chief Manufacturing Officer
--
--
Mr. Tam (Raymond) Man Kin
Mr. Tam (Raymond) Man Kin
Chief Financial Officer, Director
Chief Financial Officer, Director
--
--
Ms. Gu (Vicky) Chunfang
Ms. Gu (Vicky) Chunfang
Senior Director of Finance
Senior Director of Finance
--
--
Ms. Zhou Ling
Ms. Zhou Ling
Senior Director of Human Resources
Senior Director of Human Resources
--
--
Ms. Li Yan
Ms. Li Yan
Senior Vice President of Bioinformatics and Information Technology
Senior Vice President of Bioinformatics and Information Technology
--
--
Ms. She (Kristine) Xiaohong
Ms. She (Kristine) Xiaohong
Senior Vice President, Head of Clinical Operations
Senior Vice President, Head of Clinical Operations
--
--
Dr. Liu Guizhong, Ph.D.
Dr. Liu Guizhong, Ph.D.
Head of Biology and Pharmacology
Head of Biology and Pharmacology
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Peter (Peizhi) Luo, Ph.D.
Dr. Peter (Peizhi) Luo, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
1.31M
-46664.00%
Dr. Fangyong (Felix) Du, Ph.D.
Dr. Fangyong (Felix) Du, Ph.D.
Chief Technology Officer
Chief Technology Officer
--
--
Dr. Xu Jc, M.D., Ph.D.
Dr. Xu Jc, M.D., Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Zhao Qinghai, Ph.D.
Mr. Zhao Qinghai, Ph.D.
Chief Manufacturing Officer
Chief Manufacturing Officer
--
--
Mr. Tam (Raymond) Man Kin
Mr. Tam (Raymond) Man Kin
Chief Financial Officer, Director
Chief Financial Officer, Director
--
--
Ms. Gu (Vicky) Chunfang
Ms. Gu (Vicky) Chunfang
Senior Director of Finance
Senior Director of Finance
--
--
収益内訳
FY2024
FY2023
FY2022
FY2021
FY2020
会社から関連データがまだ開示されていません。
地域別USD
会社名
収益
比率
China (Mainland)
103.20K
0.00%
事業別
地域別
会社から関連データがまだ開示されていません。
株主
更新時刻: Sat, Feb 7
更新時刻: Sat, Feb 7
株主統計
種類
株主統計
株主統計
比率
Smith (Vincent C)
10.81%
General Atlantic LLC
8.03%
Olive Tree Capital
7.57%
WuXi AppTec Co, Ltd.
7.00%
Panacea Venture
4.77%
他の
61.82%
株主統計
株主統計
比率
Smith (Vincent C)
10.81%
General Atlantic LLC
8.03%
Olive Tree Capital
7.57%
WuXi AppTec Co, Ltd.
7.00%
Panacea Venture
4.77%
他の
61.82%
種類
株主統計
比率
Individual Investor
13.58%
Investment Advisor
13.28%
Venture Capital
12.37%
Private Equity
8.03%
Corporation
1.93%
Hedge Fund
0.35%
Research Firm
0.16%
Investment Advisor/Hedge Fund
0.02%
他の
50.28%
機関投資家保有株
更新時刻: Mon, Dec 8
更新時刻: Mon, Dec 8
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q4
34
16.13M
33.64%
--
2025Q3
35
16.13M
34.15%
+1.22M
2025Q2
33
14.91M
35.61%
-1.53M
2025Q1
31
16.44M
41.65%
-3.18M
2024Q4
29
17.99M
26.58%
+3.27M
2024Q3
27
14.73M
28.57%
+3.50M
2024Q2
28
11.22M
29.45%
-1.07M
2024Q1
30
12.30M
23.60%
+1.88M
2023Q4
27
7.12M
26.44%
-1.20M
2023Q3
33
8.32M
27.49%
-14.57K
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
General Atlantic LLC
3.78M
8.03%
-43.61K
-1.14%
Sep 30, 2025
Olive Tree Capital
3.57M
7.57%
--
--
Feb 28, 2025
WuXi AppTec Co, Ltd.
3.30M
7%
-685.45K
-17.21%
Sep 30, 2025
Panacea Venture
2.25M
4.77%
+2.25M
--
Sep 30, 2025
HSG Holding Ltd.
1.34M
2.85%
--
--
Sep 30, 2025
Luo (Peter)
1.31M
2.77%
-46.66K
-3.45%
Feb 28, 2025
Impresa Management LLC
1.29M
2.74%
+1.29M
--
Feb 28, 2025
GP Healthcare Capital Co., Ltd.
910.00K
1.93%
+910.00K
--
Feb 28, 2025
Mill Creek Capital Advisors, LLC
199.61K
0.42%
--
--
Sep 30, 2025
詳細を見る
関連ETF
銘柄名
比率
データなし
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
配当落ち日
種類
比率
データなし
日付
配当落ち日
種類
比率
データなし
